Asked by: Kate Osamor (Labour (Co-op) - Edmonton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase access to FibroScan testing for liver fibrosis through Community Diagnostic Centres.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
There are currently plans for 12 community diagnostic centres (CDCs) to offer FibroScan testing, of which six are operational. A further six CDCs plan to offer this service by the end of March 2024.
The CDC core diagnostic tests offer is based on the recommendations in the Sir Mike Richards Review, and decisions on what tests are offered outside of the core requirements of CDCs is taken at a local level based on need.
The Government is working with the National Health Service to support earlier diagnosis of liver disease and identifying patients at risk. This includes plans for upgrading laboratory digital capabilities as part of the £2.3 billion diagnostics transformation programme, to ensure that labs across the country have the capability to offer Intelligent Liver Function Tests, that can effectively and quickly identify patients at high risk of advanced fibrosis.
The Government is also working with the NHS to deliver and consider the result from the pilot of the community liver health check programme, which is due to deliver 22,000 FibroScans per year to communities at particular risk of liver disease. From June 2022 to September 2023, over 26,500 FibroScans were delivered through the pilots, and 8% of people scanned have already been enrolled into liver surveillance programmes. The programme is being delivered across 19 areas by Hepatitis C Operational Delivery Networks to FibroScan patients at high risk of cirrhosis or advanced fibrosis, utilising 40 FibroScan machines.
NHS England is reviewing existing liver diagnosis pathways as part of its wider diagnostic transformation work, to determine what the best approach should be to identify patients at an earlier stage of liver disease, through a liver pathway starting in primary care and involving pathology labs and CDCs. This will include a combination of blood tests and FibroScans.
Asked by: Kate Osamor (Labour (Co-op) - Edmonton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help improve the diagnosis of liver disease.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
There are currently plans for 12 community diagnostic centres (CDCs) to offer FibroScan testing, of which six are operational. A further six CDCs plan to offer this service by the end of March 2024.
The CDC core diagnostic tests offer is based on the recommendations in the Sir Mike Richards Review, and decisions on what tests are offered outside of the core requirements of CDCs is taken at a local level based on need.
The Government is working with the National Health Service to support earlier diagnosis of liver disease and identifying patients at risk. This includes plans for upgrading laboratory digital capabilities as part of the £2.3 billion diagnostics transformation programme, to ensure that labs across the country have the capability to offer Intelligent Liver Function Tests, that can effectively and quickly identify patients at high risk of advanced fibrosis.
The Government is also working with the NHS to deliver and consider the result from the pilot of the community liver health check programme, which is due to deliver 22,000 FibroScans per year to communities at particular risk of liver disease. From June 2022 to September 2023, over 26,500 FibroScans were delivered through the pilots, and 8% of people scanned have already been enrolled into liver surveillance programmes. The programme is being delivered across 19 areas by Hepatitis C Operational Delivery Networks to FibroScan patients at high risk of cirrhosis or advanced fibrosis, utilising 40 FibroScan machines.
NHS England is reviewing existing liver diagnosis pathways as part of its wider diagnostic transformation work, to determine what the best approach should be to identify patients at an earlier stage of liver disease, through a liver pathway starting in primary care and involving pathology labs and CDCs. This will include a combination of blood tests and FibroScans.